After a two-year battle, a Dutch health insurer has won a lawsuit that accused AstraZeneca (AZN) of creating an unfair monopoly for one of its most popular medicines by relying on an invalidated patent to thwart lower-cost competition.

At issue was a patent for the antipsychotic tablet Seroquel, which the District Court of the Hague ruled AstraZeneca used to charge “unjustifiably” high prices to health insurers. In its 2018 lawsuit, the Menzis health insurer noted a patent had been invalidated, yet the drug maker attempted to enforce its patent rights and, consequently, a large competitor was forced to delay selling a generic version.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy